Published in Medical Verdicts and Law Weekly, December 14th, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Merck.
Report 1: Merck & Co., Inc., Whitehouse Station, New Jersey, U.S., and H. Lundbeck A/S, Denmark, announced that submission of a new drug application (NDA) for gaboxadol with the U.S. Food and Drug Administration will no longer occur in the first quarter of 2007. The companies plan to submit the NDA in mid-2007.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly